AI-generated summary
The authors report a double-blind, placebo-controlled randomized trial of 16 patients with myofascial pain dysfunction syndrome, comparing laser treatment at 660 and 890 nm with a sham-like control. They report that pain reduction was greater in the laser group than in the control group, and conclude the treatment was effective for pain reduction.
- Participants
- 16
- Who or what was studied
- Patients with myofascial pain dysfunction syndrome (masticatory muscle pain)
- Wavelengths
- 660, 890 nm
- Limits stated in the abstract
- The abstract reports a small sample of 16 patients and does not describe long-term follow-up.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm, 890 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Visual analogue scale, Placebo-controlled, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.